Dave Knapp

But what do we do for people who are already sick? That's the part of the conversation that seems to get, well, what are we just going to tell them to eat less and move more? That's been a real winning strategy for the last 40 years.

But what do we do for people who are already sick? That's the part of the conversation that seems to get, well, what are we just going to tell them to eat less and move more? That's been a real winning strategy for the last 40 years.

But what do we do for people who are already sick? That's the part of the conversation that seems to get, well, what are we just going to tell them to eat less and move more? That's been a real winning strategy for the last 40 years.

If we can just embrace a little bit of the science that we know about broken metabolism, hormonal dysregulation, then maybe we can embrace getting sick people the treatment that they deserve. And then at the same time, like we can walk and chew gum at the same time, right? clean up the food environment, and we can address people that are getting sick.

If we can just embrace a little bit of the science that we know about broken metabolism, hormonal dysregulation, then maybe we can embrace getting sick people the treatment that they deserve. And then at the same time, like we can walk and chew gum at the same time, right? clean up the food environment, and we can address people that are getting sick.

If we can just embrace a little bit of the science that we know about broken metabolism, hormonal dysregulation, then maybe we can embrace getting sick people the treatment that they deserve. And then at the same time, like we can walk and chew gum at the same time, right? clean up the food environment, and we can address people that are getting sick.

And oh yeah, by the way, if you want to bring down the cost of GLP-1s, why don't we let 503Bs continue to compound this and actually look at the fact that Novo Nordisk and Eli Lilly will never be able to meet

And oh yeah, by the way, if you want to bring down the cost of GLP-1s, why don't we let 503Bs continue to compound this and actually look at the fact that Novo Nordisk and Eli Lilly will never be able to meet

And oh yeah, by the way, if you want to bring down the cost of GLP-1s, why don't we let 503Bs continue to compound this and actually look at the fact that Novo Nordisk and Eli Lilly will never be able to meet

the demand of 100 million people in the United States alone that are living with the disease of obesity, not to mention type 2 diabetes, if we're just honest about their capacity to meet that problem, then 503B should be able to let the 503Bs cook. That's what I keep saying. That's why we created them. We created them to fill a shortage.

the demand of 100 million people in the United States alone that are living with the disease of obesity, not to mention type 2 diabetes, if we're just honest about their capacity to meet that problem, then 503B should be able to let the 503Bs cook. That's what I keep saying. That's why we created them. We created them to fill a shortage.

the demand of 100 million people in the United States alone that are living with the disease of obesity, not to mention type 2 diabetes, if we're just honest about their capacity to meet that problem, then 503B should be able to let the 503Bs cook. That's what I keep saying. That's why we created them. We created them to fill a shortage.

Now, if they just took a deeper look at this issue and made sure that this was happening on the up and up, I think we may have a different outcome.

Now, if they just took a deeper look at this issue and made sure that this was happening on the up and up, I think we may have a different outcome.

Now, if they just took a deeper look at this issue and made sure that this was happening on the up and up, I think we may have a different outcome.

It's not just physical. It creates nice little soundbite clips. But one of the things, and I realize we've gone a little long here, but if I may... One of the things that I started sort of shifting towards in 2025 for On The Pens, I said, you know, I kind of gave the history of how we started and sort of what we've become. But we've gotten a lot of media attention over the last year and a half.

It's not just physical. It creates nice little soundbite clips. But one of the things, and I realize we've gone a little long here, but if I may... One of the things that I started sort of shifting towards in 2025 for On The Pens, I said, you know, I kind of gave the history of how we started and sort of what we've become. But we've gotten a lot of media attention over the last year and a half.

It's not just physical. It creates nice little soundbite clips. But one of the things, and I realize we've gone a little long here, but if I may... One of the things that I started sort of shifting towards in 2025 for On The Pens, I said, you know, I kind of gave the history of how we started and sort of what we've become. But we've gotten a lot of media attention over the last year and a half.

I mean, we were in a Fortune magazine article right next to Eli Lilly in a big expose about them. We've been featured in Bloomberg and Fortune magazine. I'm heading out to do a health.com piece in New York City this weekend. We've had a lot of opportunities that I just never would have imagined were going to come my way.

I mean, we were in a Fortune magazine article right next to Eli Lilly in a big expose about them. We've been featured in Bloomberg and Fortune magazine. I'm heading out to do a health.com piece in New York City this weekend. We've had a lot of opportunities that I just never would have imagined were going to come my way.